# Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

> **NCT07484217** · PHASE3 · RECRUITING · sponsor: **Axsome Therapeutics, Inc.** · enrollment: 508 (estimated)

## Conditions studied

- Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

## Interventions

- **DRUG:** Solriamfetol 150 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07484217
- **Lead sponsor:** Axsome Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-23
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 508 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07484217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07484217, "Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT07484217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*